Araştırma Makalesi
BibTex RIS Kaynak Göster

Distribution of cancer cases in a city of eastern Turkey and the results of survival analysis: a retrospective cohort study

Yıl 2019, Cilt: 44 Sayı: Ek 1, 26 - 32, 29.12.2019
https://doi.org/10.17826/cumj.529414

Öz

Purpose: The aim of present study was to determine the changes in the incidence of cancer in Bingöl which is in the Nomenclature of Territorial Units for Statistics- 2 (NUTS-2) region, and to perform survival analysis on these patients.

Materials and Methods: This is a retrospective cohort study and the data was obtained from the Ministry of Health's Cancer Registry System. We examined the data of 977 cancer cases diagnosed between year 2013 and 2015 

Results: 28.7% of the patients died during the follow-up period. 30% of all cancers originated from the digestive system. The cancers of lung, stomach, colon, prostate and skin are the mostly seen in the male patients, the cancers of breast, thyroid and skin are the mostly seen in the female patients. The incidence of cancer is increasing over the years and the cancer incidence rate is higher in men. The mean follow-up period was 388 days in died patients and 1541 days in alive patients. The risk of death is increasing in the patients not undergoing surgery (RR = 2.779, HR = 3.048). In addition, the risk of death is decreasing in the patients not receiving chemotherapy (RR = 0.656, HR = 0.340). The risk of death is increasing in the patients with advanced age and the male patients.

Conclusion: The incidence of cancer is increasing. Further indepth and wider research is needed to shed more light on these findings


Kaynakça

  • 1- Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers. 2016 Jan 1;25(1):16-27.
  • 2- Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Geneva: World Health Organization; 2013 (http://apps.who.int/iris/ bitstream/10665/94384/1/9789241506236_eng.pdf, accessed 1 October 2016).
  • 3- World Health Organization. National cancer control programmes: policies and managerial guidelines. World Health Organization; 2002. (http://apps.who.int/iris/bitstream/10665/42494/1/9241545577. pdf, accessed 1 October 2016).
  • 4- TC Sağlık Bakanlığı. "Türkiye kanser istatistikleri." TC Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu.(Editörler: Gültekin, M. ve Boztaş, G) Ankara (http://kanser. gov. tr/Dosya/ca_istatistik/2009kanseraporu-1. pdf)(erişim tarihi: 24 Ekim 2016) (2014).
  • 5- Wei B, Wei H. Surgical treatment strategy for advanced gastric cancer. Zhonghua wei chang wai ke za zhi= Chinese journal of gastrointestinal surgery. 2018 Oct;21(10):1099-102.
  • 6- Raman V, Yang CJ, Deng JZ, D’Amico TA. Surgical treatment for early stage non-small cell lung cancer. J Thorac Dis 2018;10(Suppl 7):S898-S904. doi: 10.21037/ jtd.2018.01.172
  • 7- Skyrud KD, Bray F, Eriksen MT, Nilssen Y, Møller B. Regional variations in cancer survival: Impact of tumour stage, socioeconomic status, comorbidity and type of treatment in N orway. International journal of cancer. 2016 May 1;138(9):2190-200.
  • 8- Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. Cancer treatment reviews. 2001 Aug 1;27(4):201-9.
  • 9- Gulliford MC, Petruckevitch A, Burney PG. Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment. Bmj. 1991 Aug 24;303(6800):437-40.
  • 10- Dede İ, Çetin Ş. Survival Analysis in Breast Cancer Patients: Frailty Models. Acta Oncologica Turcica.;50(2):130-8.
  • 11- Renehan AG, Egger M, Saunders MP, T O'Dwyer S. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Bmj. 2002 Apr 6;324(7341):813.
  • 12- Group CC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ: British Medical Journal. 2000 Sep 2;321(7260):531.
  • 13- Nagel CI, Denson WN, Richardson DL, Kehoe SM, Miller DS, Lea JS. Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer. Clinical Ovarian and Other Gynecologic Cancer. 2013 Dec 1;6(1-2):42-5.
  • 14- Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005 May 14;365(9472):1687-717.

Türkiye’nin doğusunda bir kentte kanser vakalarının dağılımı ve yaşam analizi sonuçları: retrospektif bir çalışma

Yıl 2019, Cilt: 44 Sayı: Ek 1, 26 - 32, 29.12.2019
https://doi.org/10.17826/cumj.529414

Öz

Amaç:The aim of the
present study was to determine the changes in the incidence of cancer in a city
of Turkey, which is in the Nomenclature of Territorial Units for Statistics- 2
(NUTS-2) region, and to perform survival analysis on these patients.

Gereç ve Yöntem:The present study is
a retrospective cohort study. The data of the patients were obtained from the
Ministry of Health's Cancer Registry System. The data of 977 cancer cases
diagnosed in 2013-2015 were examined. 

Bulgular:28.7% of the patients
died during the follow-up period. 30% of all cancers originated from the
digestive system. While the cancers of lung, stomach, colon, prostate and skin
are the mostly seen in the male patients, the cancers of breast, thyroid and
skin are the mostly seen in the female patients. The incidence of cancer is
increasing over the years and the cancer incidence rate is higher in men. The
mean follow-up period was 388 days in died patients and 1541 days in alive
patients. The risk of death is increasing in the patients not undergoing
surgery (RR = 2.779, HR = 3.048). In addition, the risk of death is decreasing
in the patients not receiving chemotherapy (RR = 0.656, HR = 0.340). The risk
of death is increasing in the patients with advanced age and the male patients.

Sonuç:The incidence of
cancer is increasing. It is recommended to conduct longer-term and more
broad-based studies evaluating the treatment efficacy and the effects of
treatment types on survival.

Kaynakça

  • 1- Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiology and Prevention Biomarkers. 2016 Jan 1;25(1):16-27.
  • 2- Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Geneva: World Health Organization; 2013 (http://apps.who.int/iris/ bitstream/10665/94384/1/9789241506236_eng.pdf, accessed 1 October 2016).
  • 3- World Health Organization. National cancer control programmes: policies and managerial guidelines. World Health Organization; 2002. (http://apps.who.int/iris/bitstream/10665/42494/1/9241545577. pdf, accessed 1 October 2016).
  • 4- TC Sağlık Bakanlığı. "Türkiye kanser istatistikleri." TC Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu.(Editörler: Gültekin, M. ve Boztaş, G) Ankara (http://kanser. gov. tr/Dosya/ca_istatistik/2009kanseraporu-1. pdf)(erişim tarihi: 24 Ekim 2016) (2014).
  • 5- Wei B, Wei H. Surgical treatment strategy for advanced gastric cancer. Zhonghua wei chang wai ke za zhi= Chinese journal of gastrointestinal surgery. 2018 Oct;21(10):1099-102.
  • 6- Raman V, Yang CJ, Deng JZ, D’Amico TA. Surgical treatment for early stage non-small cell lung cancer. J Thorac Dis 2018;10(Suppl 7):S898-S904. doi: 10.21037/ jtd.2018.01.172
  • 7- Skyrud KD, Bray F, Eriksen MT, Nilssen Y, Møller B. Regional variations in cancer survival: Impact of tumour stage, socioeconomic status, comorbidity and type of treatment in N orway. International journal of cancer. 2016 May 1;138(9):2190-200.
  • 8- Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. Cancer treatment reviews. 2001 Aug 1;27(4):201-9.
  • 9- Gulliford MC, Petruckevitch A, Burney PG. Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment. Bmj. 1991 Aug 24;303(6800):437-40.
  • 10- Dede İ, Çetin Ş. Survival Analysis in Breast Cancer Patients: Frailty Models. Acta Oncologica Turcica.;50(2):130-8.
  • 11- Renehan AG, Egger M, Saunders MP, T O'Dwyer S. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Bmj. 2002 Apr 6;324(7341):813.
  • 12- Group CC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ: British Medical Journal. 2000 Sep 2;321(7260):531.
  • 13- Nagel CI, Denson WN, Richardson DL, Kehoe SM, Miller DS, Lea JS. Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer. Clinical Ovarian and Other Gynecologic Cancer. 2013 Dec 1;6(1-2):42-5.
  • 14- Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005 May 14;365(9472):1687-717.
Toplam 14 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma
Yazarlar

Burak Mete 0000-0002-0780-6176

Erkan Pehlivan 0000-0002-4361-3355

Vedat Söyiler 0000-0002-7635-787X

Yayımlanma Tarihi 29 Aralık 2019
Kabul Tarihi 12 Mayıs 2019
Yayımlandığı Sayı Yıl 2019 Cilt: 44 Sayı: Ek 1

Kaynak Göster

MLA Mete, Burak vd. “Distribution of Cancer Cases in a City of Eastern Turkey and the Results of Survival Analysis: A Retrospective Cohort Study”. Cukurova Medical Journal, c. 44, 2019, ss. 26-32, doi:10.17826/cumj.529414.